Semaglutide · research summary

Advances in pharmacologic management of obesity: oral semaglutide for weight management.

Annals of medicine and surgery (2012) · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review of the OASIS-1 and OASIS-4 randomized, double-blind, placebo-controlled phase 3 trials
“Evidence from the OASIS 1 and OASIS 4 trials demonstrates that oral semaglutide, combined with lifestyle intervention, produces clinically meaningful weight loss in adults with overweight or obesity without type 2 diabetes”

Subjects

Adults with overweight or obesity without type 2 diabetes
“The OASIS-1 trial was a phase 3, randomized, double-blind, placebo-controlled study that included adults with overweight (BMI ≥ 27 kg/m2) or obesity (BMI ≥ 30 kg/m2) without type 2 diabetes.”

Sample size

1,016 total participants across both trials (709 in OASIS-1 and 307 in OASIS-4)
“A total of 709 participants were randomly assigned in a 1:1 ratio to receive oral semaglutide 50 mg once daily (n = 334) or placebo (n = 333)”

Duration

68 weeks for OASIS-1 and 72 weeks for OASIS-4
“This study lasted for 72 weeks, which included a 1-week screening period, 64 weeks of treatment, and 7 weeks of follow-up”

Reported findings

Treatment was associated with improvements in physical function and cardiometabolic risk markers such as waist circumference, lipids, and inflammatory parameters
“Participants experienced improvements in cardiometabolic risk factors, including reductions in waist circumference, lipids, and inflammatory markers such as C-reactive protein, which may translate into long-term cardiovascular risk reduction”

Limitations stated by the authors

Trials used placebo comparators rather than active agents, had limited generalizability due to strict inclusion criteria, and durations were too short to assess long-term cardiovascular outcomes or sustained weight maintenance
“The trials used placebo comparators rather than active weight-loss agents, limiting direct insight into how oral semaglutide compares with contemporary pharmacologic alternatives.”

Source: PubMed 42866773 · DOI 10.1097/MS9.0000000000005161 · all study summaries

Study type

Review of the OASIS-1 and OASIS-4 randomized, double-blind, placebo-controlled phase 3 trials

“Evidence from the OASIS 1 and OASIS 4 trials demonstrates that oral semaglutide, combined with lifestyle intervention, produces clinically meaningful weight loss in adults with overweight or obesity without type 2 diabetes”

Reported findings

Treatment was associated with improvements in physical function and cardiometabolic risk markers such as waist circumference, lipids, and inflammatory parameters

“Participants experienced improvements in cardiometabolic risk factors, including reductions in waist circumference, lipids, and inflammatory markers such as C-reactive protein, which may translate into long-term cardiovascular risk reduction”

Limitations stated by the authors

Trials used placebo comparators rather than active agents, had limited generalizability due to strict inclusion criteria, and durations were too short to assess long-term cardiovascular outcomes or sustained weight maintenance

“The trials used placebo comparators rather than active weight-loss agents, limiting direct insight into how oral semaglutide compares with contemporary pharmacologic alternatives.”